Althea Group (ASX:AGH) - CEO, Joshua Fegan
CEO, Joshua Fegan
Source: Retail Pharmacy
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Althea (AHG) completes its first shipment of medicinal cannabis products to its local partner in South Africa, Africann
  • Africann is a licensed cannabis wholesaler who specialises in the import and distribution of medicinal cannabis in the country
  • This paves way for Althea to enter the South African medicinal cannabis market which is estimated to be worth US$667 million (A$883 million) by 2023
  • Althea has ended the day 4.69 per cent in the green with shares trading at 33.5 cents

Althea (AGH) has completed its first shipment of medicinal cannabis products to its local partner in South Africa, Africann.

Africann is a licensed cannabis wholesaler who specialises in the import and distribution of medicinal cannabis in the country.

This first shipment marks an important achievement for Althea, paving way for it to enter the emerging South African medicinal cannabis industry which is estimated to be worth US$667 million (A$883 million) by 2023.

“We are excited to have exported our initial shipment of Althea products for South Africa. This development once again reflects our ambition and progress in becoming the world’s leading supplier of cannabis-based medicines,” CEO Joshua Fegan said.

“The Althea brand continues to build trust and enduring loyalty with Healthcare Professional and patients all over the globe, with South Africa the latest country able to experience our unrivalled market access program.”

Althea’s products are now available across Australia, Africa, North America and Europe.

Althea has ended the day 4.69 per cent in the green with shares trading at 33.5 cents in an $83.95 million market cap.

AGH by the numbers
More From The Market Online

4DMedical (ASX:4DX) to take part in US Veterans study into lung damage

It's called a burn pit: where members of the US armed forces dump unwanted and contaminated…

Proteomics International subsidiary secures European patent for OxiDx technology

Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across…

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at…

Telix Boosts U.S. Presence with IsoTherapeutics Acquisition

Melbourne-based Telix Pharmaceuticals (ASX: TLX) has sealed the deal to acquire IsoTherapeutics Group, LLC